The following article features coverage from the 2019 Genitourinary Cancers Symposium. Click here to read more of Cancer Therapy Advisor‘s conference coverage.

Updated findings from a phase 3 trial indicated that abiraterone plus prednisone in combination with androgen deprivation therapy (ADT) continues to offer a survival advantage to men with newly diagnosed high-risk metastatic castration-naive prostate cancer (mCNPC).

The findings, presented at the 2019 Genitourinary Cancers Symposium, are from the final analysis of the LATITUDE trial, which compared abiraterone and prednisone plus ADT with placebo plus ADT in a cohort of 1199 patients (597 and 602 randomly assigned to the abiraterone and placebo arms, respectively). Investigators led by Karim Fizazi, MD, PhD, of Institut Gustave Roussy, Université Paris-Sud in France, conducted the analysis after a median follow-up of 51.8 months. During this time, 852 patients died: 275 (46%) in the abiraterone group and 343 (57%) in the placebo arm. Median survival was 53.3 months in the abiraterone group compared with 36.5 months in the placebo group (P <.0001). Abiraterone-treated patients had a significant 30% decreased risk of death compared with placebo recipients (HR: 0.7, 95% CI: 0.6-0.8; P <.0001).

Related Articles

In addition, abiraterone recipients had significantly improved secondary endpoints. The median time-to-pain progression was 47.4 months in the abiraterone arm compared with 16.6 months among placebo recipients (P =.0002). Second progression-free survival was 53.3 months in the abiraterone arm compared with 30.1 months in the placebo group (P <.0001). The median time to chemotherapy initiation was 57.6 months in the placebo group, and not reached in the abiraterone arm.

Treatment was ongoing for 157 patients (26.3%) in the abiraterone group. Seventy-two patients (12%) crossed over from the placebo arm to the abiraterone arm. Of these, 59 (81.9%) remained on treatment.

Read more of Cancer Therapy Advisor‘s coverage of the 2019 Genitourinary Cancers Symposium by visiting the conference page.

Reference

  1. Fizazi K, Tran N, Fein LE, et al. Final analysis of phase 3 LATITUDE study in patients (pts) with newly diagnosed high-risk metastatic castration-naïve prostate cancer (NDx-HR mCNPC) treated with abiraterone acetate + prednisone (AA+P) added to androgen deprivation therapy (ADT). Presented at: 2019 Genitourinary Cancers Symposium; San Francisco, CA; February 14-16, 2019. Abstract 141.